Oral minoxidil for late alopecia in cancer survivors.

Autor: Kuo AM; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reingold RE; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ketosugbo KF; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pan A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kraehenbuehl L; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Department of Medicine, MSKCC, Parker Institute for Cancer Immunotherapy, New York, NY, USA., Dusza S; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gajria D; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lake DE; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bromberg JF; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Traina TA; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fornier MN; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gucalp A; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., D'Alessandro BM; Canfield Scientific, Inc., Parsippany, NJ, USA., Rotemberg V; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dauscher M; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shapiro J; Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA., Goldfarb SB; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Markova A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lacouture ME; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Mario.Lacouture@nyulangone.org.; Dermatology Division, Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, New York, USA. Mario.Lacouture@nyulangone.org.; Symptom Management Program, Perlmutter Cancer Center, NYU Langone Hospital - Long Island, Mineola, New York, USA. Mario.Lacouture@nyulangone.org.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Dec; Vol. 208 (3), pp. 491-499. Date of Electronic Publication: 2024 Aug 04.
DOI: 10.1007/s10549-024-07440-5
Abstrakt: Purpose: Late alopecia, defined as incomplete hair regrowth > 6 months following cytotoxic chemotherapy or > 6 months from initiation of endocrine therapy, negatively impacts quality of life and may affect dose intensity of adjuvant therapy. This study investigates the effect of oral minoxidil in women with chemotherapy and/or endocrine therapy-induced late alopecia.
Methods: The rate of clinical response was assessed by standardized photography and quantitated with trichoscopy.
Results: Two hundred and sixteen patients (mean age 57.8 ± 13.7) were included. The most common cancer diagnosis was breast, in 170 patients (79.1%). Alopecia developed after chemotherapy in 31 (14.4%) patients, endocrine monotherapy in 65 (30.1%) patients, and chemotherapy followed by endocrine therapy in 120 (55.6%) patients. In 119 patients, standardized photography assessments were used to determine clinical change in alopecia after a median of 105 (IQR = 70) days on oral minoxidil and revealed improvement in 88 (74%) patients. Forty-two patients received quantitative trichoscopic assessments at baseline and at follow-up after a median of 91 (IQR = 126) days on oral minoxidil. Patients had clinically and statistically significant increases in frontal hair shaft density (from 124.2 hairs/cm 2 at initial to 153.2 hairs/cm 2 at follow-up assessment, p = 0.008) and occipital shaft density (from 100.3 hairs/cm 2 at initial to 123.5 hairs/cm 2 at follow-up assessment. p = 0.004). No patients discontinued oral minoxidil due to adverse events.
Conclusions: Overall, oral minoxidil was well tolerated by patients and may benefit both frontal and occipital late alopecia in cancer survivors treated with cytotoxic and/or endocrine therapy by increasing hair shaft and follicle density.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: